Physician profile
Steven Guidera
NPI 1497798078
$5,693.98
in general payments reported to CMS, 2019-2025
29 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $296 · 2021: $746 · 2022: $1,532 · 2023: $777 · 2024: $1,176 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,512.33 | 2019-2024 | Sapien 3 Ultra Resilia |
| Abiomed | $723.80 | 2019-2024 | Impella |
| Medtronic, INC. | $515.17 | 2021-2024 | Corevalve Evolut R, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $458.72 | 2019-2024 | Lokelma |
| Shockwave Medical, INC | $376.16 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Abbott Laboratories | $269.77 | 2019-2025 | Mitraclip, Cardiomems |
| Medtronic Vascular, INC. | $231.53 | 2019-2020 | |
| Boston Scientific Corporation | $219.53 | 2019-2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $155.41 | 2019-2023 | Xarelto |
| Amgen INC. | $144.22 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $126.38 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.74 | 2019-2022 | |
| Teleflex LLC | $119.22 | 2023-2025 | Guideliner, Turnpike |
| Sanofi-Aventis U.S. LLC | $88.39 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $83.48 | 2023-2024 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $82.93 | 2024 | Brite Tip Radianz, Precise Pro Rx |
| Novo Nordisk INC | $78.97 | 2023-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $55.53 | 2019-2022 | |
| Chiesi USA, INC. | $50.71 | 2019-2025 | Kengreal |
| Cardiovascular Systems INC. | $46.64 | 2019-2021 | |
| Amarin Pharma, INC. | $44.05 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.75 | 2024-2025 | Lifevest |
| Cardinal Health 200 LLC | $32.62 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $26.79 | 2025 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $21.81 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $20.69 | 2024 | Arcalyst |
| Biotronik INC. | $20.42 | 2019 | |
| Penumbra, INC. | $14.06 | 2019 | |
| Terumo Medical Corporation | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Guidera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.